Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Specialised Therapeutics to market Yondelis for PharmaMar

Executive Summary

PharmaMar SA granted Specialised Therapeutics Asia Pte. Ltd. (STA) exclusive rights to market the sarcoma therapy Yondelis (trabectedin) in Australia, New Zealand, and Southeast Asia. (Former Yondelis licensee Janssen will continue to distribute the drug in Singapore, Malaysia and Brunei until STA formally takes over marketing authorization.)
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies